Using immunoglobulins in muscular disease treatment
Autor(es): Pul Refik,Stangel Martin
Resumo: Intravenous immunoglobulins (IVIg) have been proven in the past two decades to be potent immunomodulators. This led to the licensing and recommendation of IVIg as first-line treatment for Kawasaki disease, idiopathic thrombocytopenic purpura and Guillain-Barré syndrome. To review the evidence and indications for the use of IVIg in the treatment of muscular diseases. Literature search in PubMed and of further literature cited in these articles. There are small randomised controlled trials that demonstrate the efficacy of IVIg in dermatomyositis, myasthenic crisis, Lambert-Eaton myasthenic syndrome and stiff-person syndrome. However, since there are also alternative treatments IVIgs are mostly used in these diseases as alternatives when other therapeutic approaches have failed.
Palavras-Chave: Dermatomyositis; Inclusion myositis; Intravenous immunoglobulin; Lambert-Eaton myasthenic syndrome; Muscular diseases; Myasthenia gravis; Polymyositis; Stiff person syndrome
Imprenta: Expert Opinion on Biological Therapy, v. 8, n. 8, p. 1143-1150, 2008
Identificador do objeto digital: 10.1517/14712598.8.8.1143
Descritores: Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Public health
Data de publicação: 2008
